Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study

Plain-language summary

Published 2022 in Nutrients, this work by Kim M and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

• Randomized, double-blind, placebo-controlled human trial of 12 weeks of NMN in older Japanese adults (Nutrients, 2022)
• Assessed sleep quality, fatigue, and physical-performance outcomes
• A small RCT in an older-adult population; results are preliminary and not a treatment claim

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to benefits decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.